Jeremie Calais, MD, PhD

Dr Jeremie Calais, MD, PhD, is a nuclear medicine physician specialized in cancer imaging and theranostics working at the University of California Los Angeles (UCLA) since 2016. He serves as the Director of the Theranostics and Clinical Research Programs of the Ahmanson Translational Theranostics Division and as an Associate Professor in the Department of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA). Dr. Calais, who is a certified principal investigator by the ACRP, has established a clinical Theranostics research program that combines academic investigator-initiated and industry sponsored studies using targeted radionuclide imaging and/or therapy. His goal is to improve the outcome of patients with cancer through theranostic approaches and the application of knowledge gained from preclinical models and clinical studies. Dr Calais is also an Associate Editor of The Journal of Nuclear Medicine, and a Faculty Board Member of multiple organizations and committees such as the Jonsson Comprehensive Cancer Center at UCLA, the Institute of Urologic Oncology at UCLA, the Physics and Biology in Medicine Graduate Program at UCLA, the Correlative Imaging Council (CIC) of the SNMMI, the Prostate Theranostics and Imaging Centre of Excellence (ProsTIC), Melbourne, the SWOG Cancer Research Network or the Oncidium Foundation, Belgium.

Studies

Study Status

Enrolling
On Hold
Not Enrolling
Unknown

NCT06288113

Re-Treatment With 177Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration Resistant Prostate Cancer: A Prospective Phase 2 Trial (RE-LuPSMA STUDY)

This phase II trial tests how well re-treatment with 177Lu-PSMA-617 works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic), that continues to grow or spread after the surgical removal of the testes or medical treatment to block androgen production (castration-resistant), and that has shown a favorable response to initial treatment with 177Lu-PSMA-617. 177Lu-PSMA-617 is a radioactive drug. It binds to a protein called prostate specific membrane antigen (PSMA), which is expressed by some types of prostate tumor cells. When 177Lu-PSMA-617 binds to PSMA-expressing tumor cells, it delivers radiation to the cells, which may kill them. Re-treatment with 177Lu-PSMA-617 in patients who had a favorable response to initial 177Lu-PSMA-617 treatment may improve survival outcomes and disease response in patients with metastatic castration-resistant prostate cancer.

NCT06216249

A Phase 2 Randomized Trial in Patients With Metastatic Castration Resistant Prostate Cancer to Determine the Efficacy of a Flexible Dosing Schedule of Lu-PSMA Treatment up to 12 Cycles Including Potential Treatment Holiday Periods in Comparison to the Standard Fixed Dosing Schedule of Six Cycles Every Six Weeks (FLEX-MRT)

The randomized phase 2 FLEX MRT compares a group of patients treated with LuPSMA on a flexible and extended dosing schedule including "treatment holiday" periods (investigational arm, up to 12 cycles) to a control group treated with a fixed dosing schedule of 6 treatments cycles maximum administered every 6 weeks. The flexible dosing schedule in the investigational arm, will be based on SPECT/CT response assessments obtained 24h after injection of LuPSMA therapy cycle. The response assessment during treatment holiday period will be based on PET/CT every 12 weeks.

NCT05160597

Evaluation of 68Ga-PSMA-11 PET Guided Prostate Biopsy in Men With Suspicion of Clinically Significant Prostate Cancer and Prior Negative/Inconclusive Biopsy: A Prospective Exploratory Study

This early phase I trial studies how well an image-guided prostate biopsy using the imaging agent 68Ga-prostate-specific membrane antigen (PSMA)-11 with a positron emission tomography/computed tomography (PET/CT) scan works in diagnosing prostate cancer in men with a prior negative or inconclusive prostate biopsy. PSMA is a protein that is found on the surface of prostate cancer cells. 68Ga-PSMA-11 is made up of a substance that binds to PSMA on tumor cells, linked with a radioactive substance that can then be seen on imaging scans such as PET/CT. 68Ga-PSMA-11 PET/CT-guided biopsy may help improve the detection rate of prostate cancer. This may help reduce over-diagnosis and over-treatment in men with low-risk prostate cancer and under-treatment in men with high-risk prostate cancer.

NCT04857502

99mTc-PSMA-I&S in Patients With Prostate Cancer: An Exploratory Biodistribution Study With Histopathology Validation

This exploratory study conducted under the RDRC program studies the biodistribution of 99mTc-PSMA-I&S in patients with prostate cancer who undergo pelvic lymph node dissection. Prostate specific membrane antigen (PSMA)-targeted radio-guided surgery uses the preoperative intravenous administration of a PSMA-ligand called PSMA-imaging and surgery (I&S) labeled with the gamma-emitter radioisotope Technetium-99m (99mTc). Giving 99mTc-PSMA-I&S may detect PSMA-expressing lymph nodes during surgery using a gamma probe and may help guide doctors to detect prostate cancer that has spread to the lymph nodes.

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468